UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2013

Uroplasty, Inc.
(Exact name of registrant as specified in its charter)

Minnesota
(State or other jurisdiction of
incorporation or organization

(001-32632)
 
41-1719250
Commission File No.
 
(I.R.S. Employer
 
 
Identification No.)
 
5420 Feltl Road
 
 
Minnetonka, Minnesota
 
55343
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code
 
 (952) 426-6140
 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Item 2.02.   Results of Operations and Financial Condition
 
On October 24, 2013, Uroplasty, Inc. published a press release providing information regarding its results of operations and financial condition for the quarter ended September 30, 2013.
 
Item 9.01.   Financial Statements and Exhibits
 
Exhibit 99 Press Release Dated October 24, 2013

 
SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
UROPLASTY, INC.
 
 
 
 
 
 
 
By
/s/ BRETT REYNOLDS
 
 
 
Brett Reynolds, Senior Vice President and
 
 
 
Chief Financial Officer
 

Dated:  October 24, 2013